TACR1 and neoplasm: The SP/NK-1R system can be manipulated for the following therapeutic benefits: (a) tumor cells treated with antibodies against SP, with NK-1R antagonists or NK-1R expression inhibition, promoted apoptotic mechanisms [65,83,84], and (b) halted the synthesis of cell cycle proteins occurring when tumor cells do not receive the SP stimulus.